[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chemotherapy-induced-alopecia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chemotherapy-induced-alopecia":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,42,70,98,116,134,154,181,204],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100438230","phase-2-scalp-cooling-in-mbc-100438230",false,"NCT04986579","Scalp Cooling in MBC","Assessing the Impact of Scalp Cooling in With Metastatic Breast Cancer","Inclusion Criteria:\n\n* Men and women with a diagnosis of metastatic invasive breast cancer with a ECOG PS≤2\n* Participant is ≥ 18 years old.\n* Hair present at baseline.\n* One of the following full dose chemotherapy regimens must be planned for at least 4 cycles:\n\n  * Sacituzumab govitecan (IMMU-132) 10 mg\u002Fkg administered intravenously on days 1 and 8 of each 21-day cycle\n  * Trastuzumab deruxtecan 5.4 mg\u002Fkg administered intravenously once every 3 weeks\n  * Eribulin 1.4 mg\u002Fm2 administered intravenously on days 1 and 8 of each 21-day cycle\n* The Paxman Scalp Cooling System must be initiated with the first dose of therapy in participants that elect to participate in the scalp cooling group.\n\nExclusion Criteria:\n\n* Known hematological malignancies (i.e. leukemia or lymphoma)\n* Known scalp metastases.\n* Baseline alopecia (defined CTCAE 5.0 grade \\> 0, see Appendix B)\n* Subjects with cold agglutinin disease or cold urticaria.\n* Subjects who are scheduled for bone marrow ablation chemotherapy.\n* Personal history of migraines, cluster or tension headaches as defined as actual medical diagnosis by a physician and\u002F or prescribed medications. If personal history of migraines was related to a past medical problem that is now resolved, the subject may go on study at the discretion of the Principal Investigator.\n* Subjects who have lichen planus or lupus.\n* Participants who are receiving any additional anti-cancer agents","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This research is being done to compare rates of hair loss of people with metastatic breast who use scalp cooling versus those who do not use scalp cooling after receiving standard of care treatment with either sacituzumab govitecan, trastuzumab deruxtecan, or eribulin.\n\nThe name of the study intervention involved in this study is:\n\n* Paxman Scalp Cooling System",[26,27],"Metastatic Breast Cancer","Chemotherapy-induced Alopecia",[26,27],"RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-18","ACTUAL",{"date":35,"type":33},"2021-10-07",{"date":37,"type":20},"2030-06-01",{"name":39,"class":40},"Dana-Farber Cancer Institute","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100640107","phase-2-minoxidil-with-or-without-low-level-red-light-therapy-for-improving-chemotherapy-induced-alopecia-in-breast-cancer-patients-100640107","NCT07594678","Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients","A Pilot Study of Low-Level Red-Light Therapy Combined With Topical Minoxidil Compared With Topical Minoxidil Alone in Breast Cancer Patients With Chemotherapy-Induced Alopecia","Inclusion Criteria:\n\n* Patients will be Ohio State University patients \\> 18 years old\n* Patients will have a diagnosis of breast cancer, stages I-IV\n* Patients will have been treated with a chemotherapy regimen containing either an anthracycline or taxane\n* Patients will have a loss of at least 50% of the hair on the scalp by the final chemotherapy infusion\n* Patients will NOT be pregnant or nursing women\n* Patients will NOT have a history of scarring\u002Fcicatricial alopecia or alopecia areata\n* Patients will NOT have a known sensitivity to minoxidil\n* Patients will NOT have ongoing treatment with an antibody-drug conjugate or immunotherapy\n* NOTE: There is no exclusion criteria for utilization of scalp cooling",{"count":50,"type":20},50,[23],"This phase II trial compares the safety and effectiveness of topical minoxidil alone to topical minoxidil in combination with low-level red-light therapy for improving chemotherapy-induced hair loss or thinning (alopecia). Minoxidil has been approved by the Food and Drug Administration as a treatment for hair loss. It increases blood flow in the skin and may have a direct stimulatory effect on hair follicle cells, forcing them from their resting phase into their active growth phase. Low-level light therapy is regarded as a safe and medically accepted treatment for a variety of skin conditions, including acne, scars, and psoriasis. Red light wavelengths are readily absorbed into the skin and do not contain harmful ultraviolet light. When absorbed into the skin, these wavelengths stimulate fibroblasts, which are connective tissue cells that make and secrete collagen proteins. Low-level red-light therapy may improve hair loss by stimulating hair follicles. Combining minoxidil with low-level red-light therapy may be safe and more effective at improving chemotherapy-induced alopecia than minoxidil alone.",[54,55,56,57,58],"Anatomic Stage I Breast Cancer AJCC v8","Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Chemotherapy-Induced Alopecia","NOT_YET_RECRUITING","2026-05-15",{"date":62,"type":33},"2026-05-19",{"date":64,"type":20},"2026-07-02",{"date":66,"type":20},"2027-12-31",{"name":68,"class":40},"Ohio State University Comprehensive Cancer Center",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":17,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":86,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":41},"100623491","phase-1-clinical-study-of-da-020-for-the-treatment-of-chemotherapy-induced-alopecia-100623491","NCT07397325","Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia","Inclusion Criteria:\n\n* Diagnosed with stage I or stage II breast cancer\n* Scheduled but not begun, at least 4 cycles of taxane and\u002For anthracycline-based chemotherapy.\n* Ages 18-65\n* Able to give informed consent\n\nExclusion Criteria:\n\n* Resting blood pressure outside the range of 105-140\u002F 55-99\n* Uncontrolled or severe hypertension\n* Female pattern hair loss or hair loss disorder\n* Folliculitis\n* Scalp psoriasis\n* Seborrheic dermatitis\n* Inflammatory scalp conditions such as lichen planopillaris\n* Subjects wearing wigs prior to chemotherapy\n* Use of MAO inhibitors\n* Unable to provide consent or make allotted clinical visits","FEMALE","65 Years",{"count":79,"type":20},60,[81,23],"PHASE1","Clinical Study of DA-020 as a Treatment for Chemotherapy Induced Alopecia",[84,85],"Chemotherapy Induced Alopecia","Chemotherapy Side Effects",[84,87],"Chemotherapy Alopecia","2026-04-08",{"date":90,"type":33},"2026-04-13",{"date":92,"type":20},"2026-04-16",{"date":94,"type":20},"2026-12-07",{"name":96,"class":97},"Applied Biology, Inc.","INDUSTRY",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":76,"minAge":17,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":107,"briefSummary":102,"conditions":109,"keywords":110,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":111,"startDateStruct":112,"completionDateStruct":113,"leadSponsor":115,"locationsCount":41},"100623876","early-phase-1-pharmacokinetic-study-of-da-020-100623876","NCT07402330","Pharmacokinetic Study of DA-020","Inclusion Criteria:\n\n* Healthy females, age 18-55\n* BMI: 18-30 kg\u002Fm²\n* Fitzpatrick Skin Types I-IV (to standardize absorption risk)\n* Scalp free from irritation, dermatologic disease, or damage\n* Able to refrain from using other topical scalp products\n\nExclusion Criteria:\n\n* History of cardiovascular disease, hypertension, or arrhythmia\n* Scalp infections, wounds, or significant hair loss\n* Recent use of medications that interfere with CYP enzymes or adrenergic systems\n* Known sensitivity to phenylephrine or ethanol\n* Positive drug screen or abnormal ECG at screening",true,"55 Years",{"count":79,"type":20},[108],"EARLY_PHASE1",[84,85],[84,87],{"date":90,"type":33},{"date":92,"type":20},{"date":114,"type":20},"2026-11-30",{"name":96,"class":97},{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":120,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":76,"minAge":17,"maxAge":105,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":120,"conditions":124,"keywords":125,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":69},"100595545","early-phase-1-pharmacokinetic-study-of-topical-phenylephrine-100595545","NCT07033845","Pharmacokinetic Study of Topical Phenylephrine",{"count":122,"type":20},24,[108],[84,85],[84,87],"2025-09-30",{"date":128,"type":33},"2025-10-03",{"date":130,"type":33},"2025-06-30",{"date":132,"type":20},"2025-12-28",{"name":96,"class":97},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":76,"minAge":17,"maxAge":77,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":143,"conditions":144,"keywords":145,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":69},"100574689","phase-3-clinical-study-of-da-007-for-the-treatment-of-chemotherapy-induced-alopecia-100574689","NCT06762548","Clinical Study of DA-007 for the Treatment of Chemotherapy Induced Alopecia",{"count":140,"type":20},140,[142],"PHASE3","Clinical Study of DA-007 As a Treatment for Chemotherapy Induced Alopecia",[84,85],[84,87],"2025-05-22",{"date":148,"type":33},"2025-05-23",{"date":150,"type":20},"2025-10-10",{"date":152,"type":20},"2026-11-06",{"name":96,"class":97},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":76,"minAge":161,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":41},"100476518","study-to-assess-the-ability-of-the-portable-scalp-cooling-system-pscs-to-prevent-hair-loss-100476518","NCT05484973","Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss","A Post-market Multi-center Prospective Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss in Women Receiving Specific Chemotherapy Regimens for Breast Cancer Stages I-III.","Inclusion Criteria:\n\n1. Female patients ≥ 21 years of age\n2. Documented diagnosis of breast cancer, stage I, II, or III\n3. A planned taxane-containing CT regimen in the adjuvant or neoadjuvant setting with curative intent\n4. Concomitant agents may include trastuzumab, pertuzumab, or other CT agents such as cyclophosphamide, or carboplatin Note: Targeted and\u002For hormonal therapies intended for use after completion of the taxane-containing CT regimen will not be considered part of the study treatment period, and the AMMA PSCS will not be used during the post-CT targeted and\u002For hormonal therapy period\n5. Plan to complete the current CT regimen within six months\n6. At least two years out from the last CT causing hair loss with complete recovery of hair\n7. Karnofsky17 performance status 80% or greater\n8. Willing and able to sign informed consent for this study\n9. Willing and able to complete all required study procedures\n\nExclusion Criteria:\n\n1. Patients with female pattern baldness resembling picture I-3 or higher on the Savin scale\n2. Autoimmune disease affecting hair; e.g. alopecia areata, systemic lupus with associated hair loss, others\n3. A history of whole brain radiation\n4. Plans to use a CT regimen other than those specified in the inclusion criteria; specifically, a regimen not including paclitaxel or docetaxel or a regimen including an anthracycline (AC\u002FT, EC\u002FT, TAC, etc.)\n5. Hormone therapy concurrent with CT. Hormone therapy after CT is permitted\n6. Current and\u002For prior use of hair growth products, such as Nutrafol, minoxidil, and Keranique\n7. A serious concurrent infection or medical illness which would jeopardize the ability of the patient to complete the planned therapy and follow-up\n8. History of persistent grade 2 (or higher) alopecia induced by prior chemotherapeutic regimens\n9. History of and\u002For current exposure to other agents, drugs, device, or procedure that may cause hair loss\n10. Cold sensitivity\n11. Intercurrent life-threatening malignancy\n12. Evidence of untreated or poorly controlled hyperthyroidism or hypothyroidism\n13. History or current diagnosis of any of the following: Cold agglutinin disease, cryoglobulinemia, or cryofibrinogenemia\n14. Concurrent hematologic malignancy\n15. Participation in any other clinical investigation\n16. Concurrent treatment with any investigational agent\n17. Any reason the investigator does not believe the patient is a good candidate for the study","21 Years",{"count":163,"type":20},99,[165],"NA","The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.",[168,27,169,170],"Alopecia","Hair Loss","Breast Cancer","2025-04-03",{"date":173,"type":33},"2025-04-06",{"date":175,"type":33},"2024-11-08",{"date":177,"type":20},"2026-09-30",{"name":179,"class":180},"Cooler Heads Care Inc.","OTHER_GOV",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100576498","the-lily-device-trial-100576498","NCT06786078","The Lily Device Trial","PREVAIL: a Clinical Investigation on Providing Reduced Effects of Visible Alopecia Caused by Chemotherapy Using the Lily Device - a Safety and Efficacy Study.","PREVAIL","Inclusion Criteria:\n\n1. Adults ≥ age 18 with breast cancer stage 1, 2 or 3, who have been deemed appropriate for (neo-)adjuvant chemotherapy and have not yet begun any systemic therapy.\n2. Planned intravenous chemotherapy in the adjuvant or neoadjuvant setting with at least 4 cycles of chemotherapy, with one of the following regimens:\n\n   * Doxorubicin 60 mg\u002Fm\\^2 with cyclophosphamide 600 mg\u002Fm\\^2 every 2-3 weeks\n   * Doxorubicin 60 mg\u002Fm\\^2 with fluorouracil 500 mg\u002Fm\\^2 and cyclophosphamide 500 mg\u002Fm\\^2 every 2-3 weeks\n   * Paclitaxel 80-90 mg\u002Fm\\^2 weekly (every 3 weeks constitutes a cycle)\n   * Paclitaxel 175 mg\u002Fm\\^2 every 2-3 weeks\n   * Paclitaxel 80-90 mg\u002Fm\\^2 weekly (every 3 weeks constitutes a cycle) with carboplatin AUC 1.5 every week\n   * Paclitaxel 80-90 mg\u002Fm\\^2 weekly (every 3 weeks constitutes a cycle) with carboplatin AUC 5-6 every 3 weeks\n   * Docetaxel 75-100 mg\u002Fm\\^2 every 3 weeks\n   * Docetaxel 75 mg\u002Fm\\^2 with cyclophosphamide 600 mg\u002Fm\\^2 every 3 weeks\n   * Docetaxel 75 mg\u002Fm\\^2 with carboplatin AUC 5-6 every 3 weeks\n\n     * Concurrent administration with targeted agents\u002Fimmunotherapy at standard doses (such as trastuzumab, pertuzumab, pembrolizumab) is allowed. Duration of targeted agents\u002Fimmunotherapy is at the investigator's discretion.\n     * Participants on AC-T regimens who are prescribed with at least 4 treatments with anthracycline followed by at least 4 treatments with taxane are eligible for the study. In terms of data analysis, these participants are counted towards the anthracycline group\n3. Head size within the specified study sizing range.\n4. Plan to complete chemotherapy in ≤ 12 months.\n5. Willing and able to sign informed consent.\n6. Willing to comply and tolerate all study procedures including:\n\n   * Wearing the Lily device for the prescribed duration (device to be fitted before chemotherapy infusion, and worn during infusion and for at least two (2) hours and up to four (4) hours post infusion),\n   * Complete all study related questionnaires.\n   * Having photographs taken of the head at each visit.\n\nTo note:\n\n* Participants who experience a hypersensitivity reaction to chemotherapy are allowed to continue in the study if the standard doses are maintained.\n* Participants on the chemotherapy plan KEYNOTE-522 are eligible for this study.\n* If a participant is prescribed a different chemotherapy treatment plan, they may be eligible for the study only if prior Sponsor approval is obtained.\n\nExclusion Criteria:\n\n1. Baseline alopecia defined as CTCAE v5.0 grade \\> 0.\n2. History of autoimmune disease associated with hair loss, e.g., alopecia areata, systemic lupus.\n3. History of whole brain irradiation.\n4. Recent chemotherapy (≤ 2 years), which caused hair loss.\n5. Participants who are receiving or are planning to receive hormone replacement therapy or anti-estrogen therapy during the study, whereby the therapy in question has a known profile for causing hair loss.\n6. Prescribed chemotherapy regimen with concurrent administration of taxane-based and anthracycline-based chemotherapy (i.e., infusion of both taxane and anthracycline agents on the same day).\n7. Positive pregnancy test at baseline for participants with childbearing potential, as per standard of care for chemotherapy patient.\n8. Known or suspected allergy or hypersensitivity to any component of the Lily device that comes into contact with the study participant.\n9. Participants with a history of Temporomandibular Joint Disorder.\n10. Any open wounds or sores on the participant's scalp or on part of the face where the device will be applied, which in the opinion of the investigator will not be healed prior to chemotherapy commencing.\n11. Serious infection or medical illness which would jeopardize the ability of the participant to complete the planned chemotherapy.\n12. Intercurrent life-threatening malignancy.\n13. An existing history of scalp metastases or suspicion of presence of scalp metastasis.\n14. Use of a cold cap, scalp cooling device or any other hair loss reduction device during the study.\n15. Participants who, in the opinion of the investigator, will be inappropriate for inclusion into this study or will not comply with requirements of the study.\n16. Participants who do not have the mental or physical ability to comply with time schedules and further study procedures.\n17. Current participation in a clinical study or within the last 30 days prior to screening that may cause hair loss.\n18. Participation in this study at an earlier stage.",{"count":190,"type":20},85,[165],"The goal of this clinical trial is to test if the Lily Device works to reduce chemotherapy induced hair loss in patients. It will also learn about the safety of the Lily Device. The main questions it aims to answer is:\n\n* Do patient preserve their hair using the Lily Device after 4 cycles of chemotherapy, when hair preservation is a Grade ≤1 graded by an independent healthcare professional on the Common Terminology Criteria for Adverse Events (CTCAE)?\n* What is the subject incidence of Grade 1 or above Adverse Device Events (ADE's)?",[84],"2025-01-14",{"date":196,"type":33},"2025-01-22",{"date":198,"type":33},"2024-12-20",{"date":200,"type":20},"2025-11",{"name":202,"class":97},"Luminate Medical, Inc.",5,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":76,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":215,"conditions":216,"keywords":217,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":69},"100452882","photobiomodulation-therapy-in-the-prevention-and-management-of-chemotherapy-induced-alopecia-100452882","NCT05177289","Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-Induced Alopecia","Evaluating the Feasibility and Efficacy of Photobiomodulation Therapy in the Prevention and Management of Chemotherapy-induced Alopecia: a Randomized Controlled Trial","HairLight","Inclusion Criteria:\n\n* Diagnosed with gynecological cancer (endometrium, cervix, ovarian or vulva) or breast cancer\n* Receiving chemotherapy ((Carbo)-Taxol)\n* Age ≥ 18 years\n* Able to comply to the study protocol\n* Able to sign written informed consent\n\nExclusion Criteria:\n\n* Metastatic disease\n* Pregnancy\n* Active infection of the scalp\n* Previous diagnosis of a hair loss condition\n* Interruption of chemotherapy for more than two consecutive cycles\n* Medication to stimulate hair growth (e.g., Minoxidil)\n* Severe psychological disorder or dementia.\n* Inability to speak and understand Dutch\n* Substance abuse patients or patients with medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results as judged by the investigator\n* Any condition that is unstable or could affect the safety of the patient and their compliance in the study as judged by the investigator",{"count":213,"type":20},72,[165],"This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the prevention and management of chemotherapy-induced alopecia (CIA). Therefore, we hypothesize that PBMT can reduce the severity of CIA in gynecological and breast cancer patients, increasing the patient's QoL.",[27],[218],"Photobiomodulation therapy","2023-09-28",{"date":221,"type":33},"2023-09-29",{"date":223,"type":33},"2022-02-28",{"date":225,"type":20},"2030-01",{"name":227,"class":40},"Jessa Hospital"]